SOP Lithiumaugmentation

Lithiumaugmentation ist eine additive, gut evaluierte Therapiemethode zur Behandlung akuter Depressionen. Sie wird für Patienten eingesetzt, die auf einen Therapieversuch mit einem Antidepressivum nicht angesprochen haben.

• Literatur

• 1 Burgess S, Geddes J, Hawton K. et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001; (03) CD003013
• 2 Severus E, Taylor MJ, Sauer C. et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord 2014;
• 3 Bauer M, Crossley NA, Gerber S, Bschor T. The Acute Antidepressive Effects of Lithium: From Monotherapy to Augmentation Therapy in Major Depression. In: Bauer M, Grof P, Müller-Oerlinghausen B. eds. Lithium in Neuropsychiatry. The Comprehensive Guide. London: Informa healthcare; 2006: 109-127
• 4 Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68: 935-940
• 5 Nelson JC, Baumann P, Delucchi K. et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 2014; 168: 269-275
• 6 DGPPN, BÄK, KBV, AWMF, Hrsg. für die Leitliniengruppe Unipolare Depression*. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Langfassung. 2. Auflage. Version 5. 2015. http://www.depression.versorgungsleitlinien.de Stand: 10.04.2017 (* Organisationen, die in der Leitliniengruppe kooperierten: DGPPN, BÄK,KBV, AWMF, ACKPA, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW, BDK, BDP, BPM, BVDN, BVDP, BVVP, CPKA, DÄVT, DFT, DGGPP, DGPT, DGVT, DPG, DPV, DPtV, DVT, GwG, Stiftung Deutsche Depressionshilfe)
• 7 Dé Montigny C, Grunberg F, Mayer A. et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981; 138: 252-256
• 8 Bschor T. Lithium in the treatment of major depressive disorder. Drugs 2014; 74: 855-862
• 9 Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 2003; 64 (Suppl. 05) 44-52
• 10 Cipriani A, Pretty H, Hawton K. et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819
• 11 Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104: 163-172
• 12 Bschor T, Bauer M. Is successful lithium augmentation limited to serotonergic antidepressants?. J Clin Psychopharmacol 2004; 24: 240-241
• 13 Bschor T, Berghöfer A, Ströhle A. et al. How long should the lithium augmentation strategy be maintained? A 1-year follow up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 2002; 22: 427-430
• 14 Bauer M, Bschor T, Kunz D. et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157: 1429-1435